Matriks Biotek SHIKARI® Q-ATI (semi-quantitative)
Enzyme immunoassay for the semi-quantitative determination of total and free antibodies to infliximab in human serum and plasma.
Infliximab (Remicade) was associated to the development of anti-Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remicade®. This might lead to severe complications. Free and Total Anti drug Antibody monitoring is highly importance along with measuring free drug from samples. Matriks Biotek Shikari Q-ATI semi-quantitative ELISA Kit measures Free and Total anti drug antibodies to Infliximab simultaneously on the same plate.
Total and Free (Semi-Quantitative) Specifications:
|Required Volume (µl)||10|
|Total Time (min)||95|
|Detection Limit (ng/mL)||15|
|Spike Recovery (%)||-|
|Shelf Life (year)||1|
For Research Use Only
Manufactured by Matriks Biotek Co.
Questions about this product? Ready to place an order? Email us at firstname.lastname@example.org or give us a call: (650) 486-1541